Therapeutic Resolution of Pulmonary Arterial Hypertension

Dear Colleagues,

Pulmonary Arterial Hypertension (PAH) is a devastating cardiovascular disorder caused by the narrowing of blood vessels in the lungs and, in the absence of therapy, leads to right heart failure and premature death. Approximately 150,000 subjects suffer from pulmonary hypertension across the EU, USA and Japan. The genetic architecture of PAH has been explored over the last twenty years, identifying a number of genes, including BMPR2, ALK1, ENG, TGFBRII, BMPR1B, BMP9, TBX4, EIF2KA4, ATP13A3, AQP1 and SOX17, and highlighting the involvement of numerous pathways and risk factors for exploration.

There is no cure for this disorder. Current management therapies for PAH are very costly and aim to improve symptoms. After an initial response, all PAH patients develop resistance to these therapies, leading to premature death. Hence, there is a need to identify novel therapeutic interventions.  

This Special Issue of BioChem will pay attention to the recent advances in PAH research. Topics include, but are not limited to:

• Molecular genetic basis of PAH
• The role of epigenetics in the pathogenesis of PAH
• Repurposing established drugs for the resolution of PAH
• Therapeutic resolution of PAH using natural products
• Current treatments of PAH and their limitations
• The prospects of biologics for the treatment of PAH
• Resolution of PAH using small molecule agents and gene therapy

Dr. Talat Nasim
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. BioChem is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• pulmonary arterial hypertension (PAH)
• transforming growth factor β signaling pathway
• FDA approved drugs
• natural products
• drug discovery
• gene therapy
• biologics
• small molecule agents